Q1 2019

Source filing unavailable

Q1 2019 · —

Revenue—

Net Income

-$36.84M

N/M vs Q1 2018

EPS Diluted

-$24.29

no prior Q1 2018 on file

Operating Income-$37,227,000—

Operating Cash Flow-$9,897,000—

Free Cash Flowderived-$10,207,000—

Same quarter

Metric	Q1 2019	Q1 2018
Net Income	-$36.84M	-$6.94M
EPS Diluted	-$24.29	—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fulcrum Therapeutics, Inc. · CIK 1680581 · Engraved from SEC EDGAR